PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
15-Aug-2024 Phastar named in 2024 Environment 100 List Phastar
14-Aug-2024 OrganaBio Manufactures First GMP Cryopreserved Leukopaks for Two New Biopharma Partners’ Allogeneic Cell Therapies OrganaBio
14-Aug-2024 Blue Earth Therapeutics Ltd Announces Expansion of Partnership With Seibersdorf Labor GmbH to Include Manufacture of Therapeutic Radiopharmaceutical, 225Ac-rhPSMA-10.1 Blue Earth Therapeutics Ltd
14-Aug-2024 SpyBiotech Appoints Dr. Prakash Bhuyan as Chief Medical Officer SpyBiotech
14-Aug-2024 Breakthrough heart MRI technique accurately predicts heart failure risk in general population The University of East Anglia (UEA)
14-Aug-2024 Cellomatics underpins continued US and European expansion with two business development hires Cellomatics Biosciences
14-Aug-2024 Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026 Santhera Pharmaceuticals
14-Aug-2024 New scientific article on NeuroRestore ACD856 and its improved cognition and disease modification of Alzheimer’s disease New scientific article on NeuroRestore ACD856 and its improved cognition and disease modification of Alzheimer’s disease
14-Aug-2024 PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors PureTech Health plc
14-Aug-2024 NEJM publishes positive results for nipocalimab Phase 2 UNITY clinical study for early onset severe (EOS) haemolytic disease of the foetus and newborn (HDFN). Johnson & Johnson
14-Aug-2024 ViroCell Biologics completes oversubscribed financing ViroCell Biologics
14-Aug-2024 Blue Earth Therapeutics Ltd Announces Expansion of Partnership With Seibersdorf Labor GmbH to Include Manufacture of Therapeutic Radiopharmaceutical, 225Ac-rhPSMA-10.1 Blue Earth Therapeutics
12-Aug-2024 Biopharmaceuticals Market is Predicted to Reach $974 Billion with a CAGR of 12% by 2030 Next Move Strategy Consulting
09-Aug-2024 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024 Nxera Pharma
09-Aug-2024 Levicept Announces Positive Results of Phase II Trial of novel Neurotrophin-3 Inhibitor, LEVI-04, for the Treatment of Patients with Moderate to Severe Osteoarthritis Levicept
09-Aug-2024 Valneva Scotland Receives Prestigious Award for Health and Safety Excellence Valneva
07-Aug-2024 CLINIGEN ACQUIRES KINESYS CONSULTING TO BOLSTER REGULATORY AFFAIRS EXPERTISE Clinigen
07-Aug-2024 XF-73 treatment of MRSA burn wound infection prevents bacterial invasion of the bloodstream Destiny Pharma plc
07-Aug-2024 CellProthera begins long-term observational study to demonstrate safety and efficacy of ProtheraCytes® cell therapy in acute myocardial infarction CellProthera
07-Aug-2024 New results from AlzeCure's pain project TrkA-NAM presented at the pain conference IASP 2024 AlzeCure Pharma AB